IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

57 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-03

Study Completion Date

2022-06-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and tolerability and to determine the dose of IPH5201 that can be used as monotherapy or in combination with durvalumab +/- oleclumab in subjects with advanced solid tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors

NCT03665129

Advanced Solid Tumors

TERMINATED PHASE1

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

NCT02637531

Advanced Solid Tumors (Part A/B/C/D) Non-small Cell Lung Cancer (Part E) Melanoma (Part E) +5 more

UNKNOWN PHASE1

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

NCT05753722

Advanced or Metastatic Solid Tumors Non Small Cell Lung Cancer NSCLC

RECRUITING PHASE1

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

NCT03522142

Advanced Solid Tumors

TERMINATED PHASE1

A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

NCT03762447

Solid Tumors

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study D6770C00001 is a Phase 1, first-in-human, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, and immunogenicity of IPH5201 in adult subjects with advanced solid tumors, when administered as monotherapy or in combination with durvalumab ± oleclumab.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IPH5201

Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years

Intervention Type BIOLOGICAL

durvalumab

Durvalumab Q3W for a maximum of 2 years

Intervention Type BIOLOGICAL

oleclumab

Oleclumab Q3W for a maximum of 2 years

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult subjects; age ≥ 18 years
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
* Subjects diagnosed with advanced solid tumors.
* For Part 1 and Part 2 (IPH5201 in monotherapy or combined with durvalumab):Subjects must be refractory to standard therapy or for which no standard therapy exists.
* For Part 3 (IPH5201 combined with durvalumab and oleclumab): Subjects must have received and radiologically progressed on 1 prior line of systemic therapy for metastatic pancreatic ductal adenocarcinoma.
* Subjects must have at least 1 measurable lesion according to RECIST v1.1.
* Subjects must provide tumor specimens .

Exclusion Criteria

* Receipt of any conventional or investigational anticancer therapy (anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies) within 21 days of the planned first dose.
* Receipt of agents targeting CD73, CD39, or adenosine receptors.
* Concurrent enrollment in another therapeutic clinical study.
* Any toxicity (excluding alopecia) from prior standard therapy that has not been completely resolved to baseline at the time of consent.

* No toxicity leading to permanent discontinuation of prior IO therapy
* Subjects must not have required the use of additional immunosuppression other than corticosteroids
* Active or prior documented autoimmune or inflammatory disorders within the past 5 years
* Cardiac and vascular criteria:

* Presence of myocardial infarction or unstable angina , or stroke, within 6 months.
* Congestive heart failure, serious cardiac arrhythmia requiring medication, or uncontrolled hypertension
* History of severe hypertension
* History of any grade of blood clot within 6 months
* Active infection, including tuberculosis; hepatitis B virus (HBV); hepatitis C virus (HCV); or human immunodeficiency virus (HIV)
* Uncontrolled illness including certain lung diseases, uncontrolled diabetes, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study.
* Other invasive malignancy within 2 years.
* Major surgery within 28 days prior to first dose
* Female subjects who are pregnant or breast feeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

101 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No